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Methicillin-resistant Staphylococcus aureus (MRSA) blood stream infection (BSI) is a major healthcare burden
in some but not all healthcare settings, and it is associated with 10%–20% mortality. The introduction of man-
datory reporting in England of MRSA BSI in 2001 was followed in 2004 by the setting of target reductions for all
National Health Service hospitals. The original national target of a 50% reduction in MRSA BSI was considered
by many experts to be unattainable, and yet this goal has been far exceeded (∼80% reduction with rates still
declining). The transformation from endemic to sporadic MRSA BSI involved the implementation of serial na-
tional infection prevention directives, and the deployment of expert improvement teams in organizations failed
to meet their improvement trajectory targets. We describe and appraise the components of the major public
health infection prevention campaign that yielded major reductions in MRSA infection. There are important
lessons and opportunities for other healthcare systems where MRSA infection remains endemic.
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Why Did Methicillin-Resistant Staphylococcus aureus
Become Such a Problem?
Staphylococcus aureus has been recognized for over a
century as a major cause of infection, including health-
care-associated infections (HCAIs). In the early 1940s,
almost all S aureus strains were susceptible to penicillin,
but by 1960, 95% of hospital strains were resistant due
to selection of penicillinase (β-lactamase)-producing
strains. Meticillin (formerly methicillin), and later oxa-
cillin, cloxacillin, and ﬂucloxacillin, were developed to
resist staphylococcal β-lactamase and restore treatment
options. However, within 1 year of its introduction in
1960, the ﬁrst methicillin-resistant S aureus (MRSA)
strain was described [1, 2].
Methicillin-resistant S aureus infections were rare in
the 1960s, but within a decade they were causing clinical
concern, particularly in Australia, where multiple anti-
biotic-resistant strains were noted, particularly associat-
ed with infections in neonates [3, 4]. In the 1980s, some
hospitals in England had major outbreaks due to strains
that were designated “epidemic MRSA” (EMRSA), and
they required a “search and destroy” approach for their
control; ie, isolate and treat the patient, screen patient
and staff contacts for colonization, and give decoloniza-
tion treatment to anyone found to be positive [5, 6].
Two particular strains with enhanced epidemic poten-
tial (EMRSA-15, EMRSA-16) subsequently emerged in
the United Kingdom (UK) in the early 1990s, causing
excess morbidity and mortality [7–10]. The extent
of the challenge posed by these 2 epidemic strains
threatened to overwhelm the system so the search-
and-destroy approach was abandoned in many UK
institutions.
The MRSA epidemic was monitored by surveillance
of S aureus blood culture-positive cases [11]. Because
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these represent the most severe infections and are straight-
forward to deﬁne, blood should be sterile, and so a positive
blood culture likely indicates blood stream infection (BSI).
The surveillance, which involved the reporting of cases by mi-
crobiology laboratories to a national database, was undertaken
initially by the Public Health Laboratory Service and then, from
2003 to 2013, by its successor, the Health Protection Agency
(HPA). Until 2001, this surveillance was voluntary, but, aware
of rising numbers and public concern, the Government intro-
duced mandatory reporting of MRSA BSIs for all National
Health Service (NHS) hospitals in England in 2001 [12]. The
total numbers of reported MRSA BSIs (Figure 1) peaked at
7700 in 2003–2004, and the numbers declined markedly from
2006 [13, 14]. Methicillin-resistant S aureus infection had also
become the subject of considerable public and media attention:
headlines referred to “MRSA massacres”, “plagues”, “super-
bugs”, and “squalid hospitals”. Thus, control of MRSA became
a political priority.
Why did this happen? As MRSA BSIs increased in the 1990s,
many assumed that these were replacing infections caused by
methicillin-susceptible S aureus (MSSA) strains; in fact, they
were additional to MSSA BSIs (which were also increasing)
[15]. During the last quarter of the 20th century, infections (in-
cluding HCAIs) were not regarded as priority areas. Antibiotics
and vaccines were thought to provide the answer to infection,
and clinical hygiene, aseptic practice, and other prevention and
control measures received scant attention during clinical or
management training. Crucially, there was a failure to appreciate
Figure 1. Numbers of methicillin-resistant Staphylococcus aureus (MRSA) blood stream infections (BSIs) reported in England, 1990–2012. Vertical ar-
rows indicate notable interventions aimed at reducing MRSA BSIs: 1, introduction of mandatory reporting of MRSA BSIs; 2, launch of national report
targeting 7 key areas for improvement (active surveillance and investigation, infection risks associated with medical devices, reservoirs of infection, stan-
dards of hygiene in clinical practice, prudent use of antimicrobials, management and organization, and research and development; 3, launch of the clea-
nyourhands campaign to improve the standard of hand hygiene, which required alcohol hand gel to be available, as a minimum, at all points of patient
contact; 4, launch of MRSA/Cleaner Hospitals Improvement Programme and, in November 2004, announcement of mandatory target to halve the number of
MRSA BSIs in hospitals in England by 2008; 5, legislation was introduced in 2006, which implemented a statutory Code of Practice on healthcare-associated
infection (HCAI) that applied to all National Health Service (NHS) healthcare providers; 6, in late 2007 a series of additional measures was added, including
a requirement for quarterly reporting on HCAIs to hospital Boards, an extension of the cleanyourhands campaign, and a legal requirement for hospital Chief
Executives to report MRSA BSIs (and Clostridium difﬁcile infections) centrally more frequently (within 2 weeks of each following month); 7, start of sig-
niﬁcant reductions in cephalosporin and ﬂuoroquinolone prescribing in hospitals; 8, MRSA screening implementation guidance was issued during 2008,
stating that screening of elective and emergency admissions should be occurring by March 2009 and December 2010, respectively.
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that although medical progress was increasing life expectancy,
many medical interventions (eg, surgery, catheter use, im-
munomodulation) increased the risk of nosocomial infection.
Notably, there was a lack of robust data on the proportion of
preventable HCAIs.
How Has Methicillin-Resistant Staphylococcus aureus
Infection Been Controlled in England?
There has been no single “silver bullet” to address the challenge
of MRSA infection. Instead, multiple infection prevention and
control (IPC) initiatives, targeting different aspects and levels of
healthcare, took place (Table 1) [16–57]. Senior managers and
clinicians were required to ensure that interventions were a
major priority across organizations, with a zero tolerance ap-
proach to MRSA and other HCAIs. Thus, a culture change
was needed to place IPC at the heart of healthcare practice, in-
cluding a shift from reactive to proactive surveillance and prac-
tice audit. However, a zero tolerance approach does not mean
that there will be no infections. Instead, the aim was to mini-
mize infection risks, with implementation of improved clinical
practice protocols, particularly for hand hygiene (hand washing
and use of alcohol hand rubs) [31], environmental cleaning, and
disinfection [27, 32], including a series of high-impact inter-
ventions (HIIs) in the form of care bundles, particularly for in-
vasive procedures with a high risk of infection [36, 39].
The response to the public health threat posed by MRSA in-
fection was underpinned by an improvement program and a
target to halve MRSA BSIs by 2008 (baseline 2003–2004) [33,
34]. Legislation was introduced in 2006, which implemented a
statutory Code of Practice on HCAI that applied to all NHS and
independent (2008) healthcare providers [41, 58].
The Early Years (2000–2005): The New Millennium Challenge
The (voluntary) Nosocomial Infection National Surveillance
Scheme (NINSS) for England and Wales, established in 1996,
covered several infections including BSIs and postoperative in-
fections; NINSS extended a long-standing system for reporting
all clinically signiﬁcant bacteremias [11, 59]. In April 2001,
mandatory surveillance of MRSA BSIs was introduced in En-
gland [12, 22]. All MRSA-positive blood cultures had to be re-
ported, excepting duplicates from an individual within 2 weeks.
Methicillin-resistant S aureus BSIs were apportioned to com-
munity or hospital acquisition according to whether the blood
culture was collected within the ﬁrst 48 hours of admission or
later, respectively. Methicillin-resistant S aureus BSIs occurring
in each hospital were initially reported annually, but no reduc-
tion target was set.
A report by the Chief Medical Ofﬁcer (CMO) for England led
to the creation of the HPA in 2003, and it identiﬁed priority
areas in infectious diseases, including HCAIs and antimicrobial
resistance [23]. The HPA had responsibility for surveillance, in-
cluding the mandatory surveillance of MRSA BSIs in England.
A second CMO report, speciﬁcally on HCAI [26], established
the need for improved surveillance and more stringent IPC
measures, with an emphasis on hand hygiene using alcohol
hand gel and aseptic practice. National Health Service hospitals
were each required to appoint a Director of IPC: that is, a senior
clinician (medical or nursing) who reports directly to the Chief
Executive and Board. In 2004, the National Patient Safety Agency
(NPSA) launched the “cleanyourhands” campaign to improve
the poor standard of hand hygiene that had been identiﬁed in
NHS hospitals [31]. This campaign was linked to the interna-
tional World Health Organization hand hygiene program
[60]. The NPSA program included publicity and educational
materials for staff, patients and relatives, and crucially required
alcohol hand gel to be available, as a minimum, at all points of
patient contact.
The Department of Health’s Active Program and a Government
Target
A National Audit Ofﬁce (NAO) report in 2004 was very critical
of progress (since 2000) in reducing HCAIs, particularly MRSA
BSIs [19, 30]. There was increasing public and media concern
about MRSA, heightened by increasing numbers of associated
deaths; MRSA accounted for 12% and 66% of all death certiﬁ-
cates that mentioned S aureus in 1993 and 2002, respectively
[35]. In 2004, an action plan focused on both hospital cleanli-
ness and infection control [27], and it led to a MRSA/Cleaner
Hospitals Improvement Program (CHIP) [34]. Notably, in No-
vember 2004, the Secretary of State for Health announced a tar-
get to halve the number of MRSA BSIs in hospitals in England
by March 2008 [33]. This target placed MRSA infection reduc-
tion on the same basis as other NHS targets, including those for
waiting times in Accident or Emergency departments and for
receiving elective hospital care. This was the ﬁrst time that
this approach had been applied to a clinical rather than ﬁnancial
or organizational outcome. Each hospital was given an expected
trajectory to reduce MRSA BSIs, which mandated a 20% reduc-
tion in each of 3 consecutive 12-month periods (2005–2008).
The MRSA/CHIP had 2 main arms. First, “improvement
teams” (ITs), comprising experienced nurses, doctors, and
managers with a good track record in IPC, visited NHS hospi-
tals to review practices and advise on improvements and imple-
mentation. Improvement teams did not have enforcement
powers, but they were highly inﬂuential, particularly because
they initially focused on hospitals (n = 20 of 170) that did not
achieve their MRSA BSI reduction trajectories. Second, a series
of guidance documents and clinical HII care bundles were pro-
duced to guide clinical practice in IPC (particularly for MRSA)
and to support education and training of clinical staff [36]. TheHII
care bundles clearly established the 5–6 essential elements to min-
imize infection risks. All elements were to be followed consistent-
ly, and the bundles incorporated simple audit tools. For MRSA
infection, the bundles focused on central and peripheral venous
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Table 1. Chronology of Key Events in MRSA BSI Control Program in England
Date Initiative Comment
March
1998
House of Lords Select Committee on Science and Technology
report “Resistance to antibiotics and other antimicrobial
agents” [16].
Recommended that the NHS should set itself targets for
controlling MRSA in hospitals and publish its achievements;
also that infection control and hygiene should be at the heart
of good hospital management and practice, and that
resources should be redirected accordingly.
February
2000
National Audit Office (NAO) 1st report: The management
and control of HAI in acute NHS Trusts in England [17].
Surveyed infection control teams (ICTs) believed that 15%
reduction in HAI was achievable. NAO observed that there
“may be a growing mismatch between what is expected of
ICTs in controlling infection and the staffing and other
resources allocated to them”.
June
2000
UK antimicrobial resistance strategy and action plan [18]. Areas for action included surveillance, prudent antimicrobial
use, and infection control. It was stated that the Department
of Health would lead the development of performance
standards and targets for HAI (including MRSA) for England
and Wales.
November
2000
Committee of Public Accounts 42nd report of session
1999–2000. The management and control of hospital
acquired infection in acute NHS Trusts in England [19].
Two main conclusions: (1) the NHS did not have a grip on the
extant of HAI; and (2) a root and branch shift towards
prevention was needed at all levels and that a philosophy that
prevention is everybody’s business not just the specialists.
January
2001
National Evidence-Based Guidelines for Preventing
Healthcare-Associated Infections in NHS Hospitals in England
(EPIC 1) published [20].
First systematic review of the evidence to support
interventions to reduce HCAI.
April 2001 National Standards of Cleanliness – NHS Estates [21]. Outcome-based standards to improve cleanliness. It was
recognized that cleaning staff had an important role in quality
improvement.
April 2001 Introduction of mandatory surveillance for MRSA BSIs.
Department of Health. Surveillance of healthcare
associated infections, CMO’s Update 30 [22].
Minimum dataset to be collected by acute hospitals in
England: (1) the total number of blood culture sets taken; (2)
the total number of positive blood cultures; (3) the total
number of blood cultures positive for Staphylococcus
aureus; (4) MRSA-positive blood cultures as a proportion of
all S aureus-positive blood cultures.
Each data set to be expressed as a proportion of all hospital
activity. Data submitted on a quarterly basis to be published
from April 2002.
January
2002
Getting ahead of the curve: a strategy for infectious
diseases [23].
Recommended the establishment of the Health Protection
Agency (HPA). Infectious disease control needed to be
transformed from a “Cinderella service” by bringing into the
mainstream of service development. Used the term “HCAI”
instead of “HAI”.
June
2003
Surveillance of healthcare associated infections [24]. From July 2003, mandatory MRSA bacteremia data to be the
basis of a performance management indicator. Data from
the 2 most recent years were to provide each Trust with an
“improvement score” as part of a balanced scorecard,
which contributed to star ratings of each acute hospital
Trust.
June
2003
Hospital Pharmacy initiative for promoting prudent use of
antibiotics in hospitals [25].
∼£12 million was allocated for 3 years from 2003 to 2004 to
pump prime clinical pharmacy initiatives around
antimicrobial prescribing in acute NHS hospital trust.
Funding often used to employ “antimicrobial pharmacists”.
December
2003
Winning Ways: working together to reduce healthcare
associated infection in England [26].
Set a clear direction for the NHS on actions to reduce the
relatively high levels of particular HCAIs. Trusts were required
to designate a Director for Infection Prevention and Control.
Seven key action areas: active surveillance and investigation;
reducing the infection risks associated with medical
devices; reducing reservoirs of infection; high standards of
hygiene in clinical practice; prudent use of antimicrobials;
management and organization; research and development.
July
2004
Towards cleaner hospitals and lower rates of infection [27]. Hospital cleanliness remained a major patient concern, and
MRSA was a growing problem. The 2 issues were
considered to be linked (from a public perspective).
August
2004
Rapid Review Panel established. Recommendation from
Winning Ways [28].
The panel provided a prompt assessment of new and novel
equipment, materials, products, or protocols that may be of
value to the NHS in improving hospital infection control and
reducing HCAI.
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Table 1 continued.
Date Initiative Comment
July
2004
National Standards Local Action - Health and Social Care
Standards and Planning Framework 2005/2006–2007/
2008 [29].
Healthcare organizations were charged to keep patients, staff,
and visitors safe by having systems to ensure that the risk of
HCAI is reduced, with particular emphasis on high standards
of hygiene and cleanliness, and achieving year-on-year
reductions in MRSA (a target for MRSA reduction to be set
for each NHS hospital Trust).
July
2004
NAO 2nd report: Improving patient care by reducing the risk of
HAI [30].
Noted that: the number of MRSA bacteremias had increased
since mandatory surveillance had been introduced, but the
data did not enable clinicians to identify and reduce risks
within their specialty; welcomed the publication of Winning
Ways; 80% of Trust Chief Executives reported that they had
made changes to their infection control arrangements since
2000, one key driver being controls assurance.
September
2004
NPSA patient safety alert about hand hygiene [31]. Instructed NHS trusts to install alcohol-based hand rub at the
point of care. Signaled the piloting of the cleanyourhands
campaign.
October
2004
A Matron’s Charter: an action plan for cleaner hospitals [32]. Emphasized the role of hospital cleanliness as an integral part
of infection control. All staff working in healthcare to receive
education in infection control.
November
2004
Introduction of mandatory target to reduce MRSA bloodstream
infections in hospitals [33].
The Secretary of State for Health announces a target to halve
the number of MRSA BSIs in hospitals byMarch 2008, using
2003–2004 as baseline. (Actually, this was a 60% reduction
target for most trusts [20% per year for 3 consecutive years]
because those with few or none could contribute little to
national [50% reduction] target.)
January
2005
MRSA/HCAI/Cleanliness Improvement Programme [34]. Originally focused on the 20 most challenged Trusts with
respect to MRSA BSI rates. Became the HCAI and
Cleanliness Improvement Programme, aiming to (1) support
hospital trusts and NHS organizations to reduce MRSA BSIs
and (2) improve public and patient confidence in the NHS.
April
2005
Office for National Statistics (ONS) Report: Deaths involving
MRSA: England and Wales, 1999–2003 [35].
The first ONS report on deaths relating to MRSA. MRSA
accounted for 66% of death certificates that mentioned S
aureus in 2002 compared with only 12% in 1993.
June
2005
Saving Lives – a delivering program to reduce healthcare
associated infection, including MRSA [36].
Focused on practice measures to reduce MRSA BSIs: high-
impact interventions were produced to improve the reliability
of clinical practice in a number of areas, including
antimicrobial prescribing and the insertion and maintenance
of invasive devices, to minimize the risk of HCAI.
June
2005
Introduction of monthly MRSA BSI reporting [37]. Reporting required by 15th of each following month.
Publication of data summaries increased in frequency from
annual to twice a year.
October
2005
Introduction of Mandatory MRSA bacteremia enhanced
surveillance scheme [38].
MRSA surveillance scheme enhanced to capture
comprehensive data via a web-enabled data capture system
on individual cases of MRSA bacteremia, including: patient
demographics; date of admission; date of bacteremia;
location at time of blood culture; consultant specialty; type of
clinical care at the time the blood sample was taken.
May
2006
Going further faster: implementing the Saving Lives delivery
program [39].
Guidance to support the delivery of the MRSA target and the
Saving Lives program. The focus was on actions that could
impact on MRSA, but these would also support system-
wide improvement in HCAI.
1 June
2006
Introduction of root cause analysis toolkit (NPSA) [40]. An action tool for clinicians and risk managers to use when a
patient had a life-threatening infection, such as MRSA
bacteremia. This helped clinical teams to identify (1) what
factors or events led to the infection and (2) how to reduce
the risks of it happening again.
October
2006
The Health Act 2006: Code of Practice for the prevention and
control of healthcare associated infections [41].
Legal requirement for managers of NHS organizations to deliver
low HCAI risk for patients. Failure to observe the Code could
result in either an Improvement Notice issued by the
Healthcare Commission or the organization being reported for
significant failings and placed on special measures.
November
2006
Summary of best practice for MRSA screening [42]. Trusts recommended to consider models for screening and
decolonization of high-risk patients (A&E and ICU
admissions, and some groups preoperative surgical patients,
eg, elective orthopedic, cardiothoracic, neurosurgical).
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Table 1 continued.
Date Initiative Comment
February
2007
EPIC 2 published [43]. Updated evidence-based guidance on standard precautions and
the insertion and optimal management of CVCs and UCs.
June 2007 Clean, safe care: reducing infections and saving lives [44]. A progress report on what had been achieved and what still
needed to be done. The NHS was on track to achieve the
MRSA target. The Healthcare Commission begins its
program of unannounced inspections of NHS trusts against
the Code of Practice.
July 2007 £50million additional funding for reducing healthcare associated
infections [45].
Additional one-off funding to be spent promptly to achieve
rapid results on reducing HCAIs. Front-line staff were
expected to be involved in the decision making and be kept
informed of where the additional money was been spent.
Each Strategic Health Authority received £5 m to allocate to
NHS organizations.
September
2007
Uniforms and work wear: An evidence base for developing
local policy [46].
Widely known as the “bare below the elbows” guidance, this
was widely adopted throughout the NHS. It supported the
requirements of the Health and Social Care Act 2008 Code
of Practice relating to the need for uniform and workwear
policies to support effective hand hygiene.
November
2007
Deep Clean campaign announced [47]. The government announced £57.5 m for deep cleaning
throughout Trusts between December 2007 and March
2008. Later NAO report estimated that £62.6 m was spent
on Deep Clean campaign. Trust Directors of Nursing were
asked to agree jointly with Directors of Estates and Facilities
what was needed and how it would be evaluated.
December
2007
Operating framework for NHS, 2008/2009 [48]. Recognized that meeting the HCAI challenge required
additional actions across the NHS for 2008/2009, including:
introducingMRSA screening for all elective admissions from
2008/2009, and for all emergency admissions as soon as
practicable within the next 3 years; and implementing the
forthcoming HCAI and Cleanliness Strategy.
The tariff uplift for 2008/2009 recognizes the importance of
tackling HCAI and improving cleanliness, and the NHS
contract sets out sanctions for failing to achieve agreed
improvements.
July
2008
MRSA screening operational guidance [49]. Supported NHS trusts in introducing MRSA screening for all
elective patients by March 2009.
September
2008
Clean Hands Save Lives. NPSA updated and reissued their
Patient Safety Alert [50].
The alert recognized the reduction in MRSA bacteremias;
however, it stated to maintain this and other improvements,
it was vital that hand hygiene remains high on the patient
safety agenda.
December
2008
Operating framework for NHS, 2009/2010 [51]. Noted that the NHS had achieved the ambitious 50% reduction
of MRSA nationally, although not in every organization: this
objective should remain their immediate goal. From April
2009, all elective admissions had to be screened for MRSA,
and this was to be extended to emergency admissions as
soon as possible and no later than 2011.
January
2009
NHS Constitution published [52]. Recognized that the NHS had met the national target to halve
the number of MRSA bloodstream infections by 2008/2009
and that it was expected to continue to reduce HCAIs.
Setting a national minimum standard for these infections
would be considered.
December
2009
Operating framework for NHS, 2010/2011 [53]. After a recommendation from the National Quality Board, from
April 2010, NHS organizations were to set an objective for
reducing MRSA infections, relative to the median, with the
best performers setting their objectives locally. The
objective reflected a zero-tolerance approach to preventable
infections and aimed to reduce variation in performance on
MRSA bloodstream infections. The MRSA objectives for
2010–2011 were calculated against yearly baseline data
from October 2008– September 2009.
March
2010
MRSA screening operational guidance 3 [54]. Supported NHS organizations in introducing MRSA screening
for all relevant emergency admissions by end of 2010.
December
2010
Operating framework for NHS, 2011/2012 [55] MRSA objectives for 2011–2012 were set using the same
methodology as the previous year. Clostridium difficile
objectives for 2011–2012 also introduced (again used a
methodology to be used for 3 years).
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catheters, renal dialysis catheters, surgical sites (wounds), ven-
tilated patients, and urinary catheters [44]. Additional bundles
were added for Clostridium difﬁcile infection (CDI), optimal
blood culture sampling, MRSA screening, and prudent antimi-
crobial prescribing [44].
In late 2007, a series of additional measures was added, in-
cluding a requirement for quarterly reporting on HCAIs by ma-
trons and clinical directors to hospital Boards, an extension of
the cleanyourhands campaign, and a legal requirement on hos-
pital Chief Executives to report MRSA BSIs (and CDIs) to the
HPA more frequently (within 2 weeks of each following month)
[47]. The Care Quality Commission was given new powers, in-
cluding annual IPC inspections of all hospitals. Compliance by
NHS staff with HCAI measures was given a new focus by the
introduction of a dress code [48]. Commonly known as “bare
below the elbows”, clinical staff were required to wear short
sleeves and not to wear wrist watches, bracelets, or rings
(other than plain wedding rings); doctors were not to wear
ties that could come into contact with patients and were to dis-
pense with the “white coat” uniform. The dress code aimed to
facilitate good hand hygiene practice, and staff were encouraged
to challenge noncompliant colleagues.
Screening for Methicillin-Resistant Staphylococcus aureus
Carriage and Colonization
Screening of patients for MRSA had been routine practice in
some hospitals in England (in high-risk surgical specialties)
for many years, but it had not been applied to all admissions.
In November 2006, MRSA screening guidance was issued
[42], linked to specialist society recommendations [61], and ad-
vised wider screening of patients admitted to high-risk special-
ties. However, implementation of this risk-based approach was
patchy. One year later, a wider approach to screening was
announced, effectively meaning that most NHS admissions
should be screened; implementation guidance was issued during
2008, stating that screening of elective and emergency admis-
sions should be occurring by March 2009 and December 2010,
respectively [46]. However, as discussed below, implementation
of MRSA screening was slow to be implemented and inconsis-
tently applied.
Where Are We Now?
During the ﬁrst half of the 3-year MRSA target program in En-
gland (2005–2008), numbers of MRSA BSIs began to decrease,
albeit slowly and not on trajectory to meet the 50% reduction
target [14]. However, as the focus on IPC measures increased,
the rate of reduction increased markedly. Thus, by 2008–2009
there had been a 62% decrease in MRSA BSIs from 7700
in 2003–2004 (baseline) to 2932 in 2008–2009. The reduction
continued to 1898 in 2009–2010 (75% reduction), 1481 in
2010–2011 (81% reduction), and 1114 (86% reduction) in
2011–2012 [14]. The MRSA BSI rates (per 100 000 population
have declined from 8.7 to 5.7 to 3.6 to 2.8 to 2.1 and to 1.7 in
2007–2008, 2008–2009, 2009–2010, 2010–2011, 2011–2012,
and 2012–2013, respectively. There has also been a change in
pattern of the underlying causes of MRSA BSIs, and a shift in
their distribution [12, 14]. Since 2010, more cases were associated
with nonhospital care than in-patient care. There has been an em-
phasis on preventing cases associated with intravascular lines and
other implanted devices. These accounted for more than half of
hospital-associated cases, with another 20% related to skin and
soft tissue infections (SSTIs). In the wider community, <30%
are associated with implanted or indwelling devices, with a similar
proportion associated with SSTIs. Notably, the reduction in BSIs
has been accompanied by a decrease in deaths in England in
which MRSA appeared on the death certiﬁcate from 1556 (480
as underlying cause) in 2006 to 485 (82) in 2010 [62].
DISCUSSION
There is an approximate north-south gradation in Europe of in-
creasing MRSA infection rates [63, 64]. In 2011, MRSA preva-
lence (as a proportion of all invasive S aureus infections, which
is a proxy indicator of the incidence of MRSA infection) was
Table 1 continued.
Date Initiative Comment
2011 National One Week Audit of MRSA screening in NHS acute
trusts [56].
Found that screening all admissions according to current
guidance is not clinically or cost effective; recommended
that all patients admitted to high-risk specialties and all
critical care units, whether elective or emergency
admissions, should be screened for MRSA. Patients
identified as carrying MRSA should be isolated and given
decolonization/suppressive therapy.
November
2011
Start Smart Then Focus launched [57]. Guidance to NHS acute Trusts on antimicrobial stewardship.
Abbreviations: A&E, accident and emergency; BSI, blood stream infections; CMO, Chief Medical Officer; CVC, central venous catheter; HAI, hospital-acquired
infection; HCAI, healthcare-associated infection; ICU, intensive care unit; MRSA, methicillin-resistant Staphylococcus aureus; NHS, National Health Service;
NPSA, National Patient Safety Agency; UC, urinary catheter; UK, United Kingdom.
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<25%, 25%–50%, or >50% in 16, 6, and 2 countries, respectively
[63]. Between 2008 and 2011, MRSA prevalence decreased sig-
niﬁcantly in 6 countries (UK, Denmark, Belgium, France,
Spain, and Ireland), and it increased signiﬁcantly in Luxem-
bourg, Hungary, Poland, and Romania [63]. In the remaining
17 European countries, no signiﬁcant changes in MRSA preva-
lence were recorded [63]. There are few systematically collected
surveillance data on MRSA infection across the United States; a
recent estimate found no statistically signiﬁcant increase in the
hospitalization rate due to MRSA between 2005 and 2009, al-
though the total number of infections increased [65]. In Asia,
MRSA has remained endemic in many hospitals over the past
decade with the majority of S aureus infections caused by
MRSA [66]. Notably, there has been a large, signiﬁcant reduc-
tion in incidence of hospital-onset MRSA and MSSA BSIs in
Australia since 2002, which coincided with the introduction
of a range of IPC activities [67].
The contrasting epidemiology of MRSA infection across coun-
tries likely reﬂects differences in the dynamics of epidemic strains
[68–71], qualitative and quantitative variation in antimicrobial
prescribing [72–74], and the reach of healthcare-improvement
projects [65, 66, 75]. The prevalence of MRSA clones may follow
a wave trajectory (initial expansion, relative stasis, then decline)
[71]. If such clones dominate in a particular area or country,
then, depending on their natural cycle of expansion or contrac-
tion, the incidence ofMRSA infection may alter accordingly. Lon-
ger observations of consistent changes in MRSA incidence make
such a phenomenon less likely to be the sole explanation for
marked changes in infection rates. A notable example of the ex-
tent of differences in MRSA BSI incidence is seen in Northern
Germany versus the Netherlands, which have similar sized pop-
ulations and share a national border [76]. There was a 32-fold
higher incidence of MRSA bacteremia in the German Northern
Rhine-Westphalia region, possibly due to differences in healthcare
structures and MRSA control strategies. Dutch MRSA control
strategy has historically been interventionist and based on rigor-
ous search-and-destroy methods [75].
In the ﬁrst decade of the new millennium, there was public
health requirement to address MRSA infection that became
both a public and political imperative in England. The control
of MRSA BSI in England has no identiﬁable key intervention,
such as the claimed role of the Broad Street pump handle over
150 years ago [77]. However, historians now argue that control-
ling the cholera outbreak was more complicated than the simple
disablement of a water pump [77]. Controlling and indeed pre-
venting infection is a multimodal process. After a 57% reduc-
tion in MRSA BSIs in England had been achieved, the NAO
noted that there had been “a cultural change in the way that
organisations tackle IPC and the priority that it is afforded”
[78]. Such statements are consistent with a very marked de-
crease in incidence of CDI in England that occurred over a sim-
ilar timescale. Healthcare-associated infection control became a
remit for whole organizations rather than the prerogative of
IPC teams alone. This shift saw an increased focus on “old-
fashioned” practices of hand hygiene, asepsis and cleanliness,
and practice changed from being reactive to proactive; hence,
from infection control to IPC. Use of root cause analysis became
commonplace in the NHS, and this enhanced not only a sense
of shared ownership of HCAI, but it facilitated learning and a
culture where suboptimal practice would be challenged [79].
Even if a root cause of a MRSA BSI could not always be iden-
tiﬁed, the process encouraged team ownership of IPC, and it
placed an emphasis on optimizing patient journeys through
the healthcare system.
There was some skepticism whether national targets were ei-
ther desirable or achievable [80]. Nevertheless, infection targets
and reduction trajectories for all NHS hospital were instrumen-
tal in changing organizational approaches to HCAI control [33].
The use of clinical endpoints in organizational performance
management was new to the NHS. The MRSA/CHIP identiﬁed
that the ﬁrst and major priorities were to address clinical proto-
cols, hand hygiene, and aseptic practice aspects of MRSA IPC.
Increased purchasing of alcohol hand products was indepen-
dently associated with reduced MRSA BSIs in England and
Wales, but this was established only in 2007–2008 (as opposed
to the previous 36 months) of the cleanyourhands campaign
[81]. This lag is in line with increased staff compliance with
bundles of interventions to reduce HCAI risk. A recent review
conﬁrmed the association between increased consumption of
alcoholic hand rub and reduced MRSA rates [82]. Notably,
the introduction of legislation in 2006 was strongly associated
with reduced MRSA BSIs (and CDI) [41, 81]. Review visits by
ITs were also signiﬁcantly associated with reduced MRSA
BSIs (and CDI) for at least 6 months after each visit [81].
These examples illustrate how it is possible to draw some con-
clusions about which interventions were likely to have been more
important in the control of MRSA. However, given the (1) mul-
timodal and often bundled interventions that were used and (2)
limited data to quantify the extent of their implementation, there
are clear limitations to drawing deﬁnitive conclusions regarding
their effectiveness. Nevertheless, it should be noted that there is
no evidence that the reduction in recorded MRSA BSIs was due
to fewer blood cultures being taken. Indeed, in 2009, a report con-
cluded that signiﬁcant reductions in MRSA BSIs (and CDIs) had
occurred, but the rates of other healthcare-associated BSIs re-
mained unaltered (Supplementary Table).
The role of screening and decolonization in the control of
MRSA infection, and BSI speciﬁcally, is less clear [83]. Coloni-
zation of the skin, nose, or throat with MRSA (and other S au-
reus strains) often precedes invasive infection, and a colonized
patient can be at risk of developing an endogenous infection or
of being a source for transmission [84].Therefore, screening pa-
tients on admission, coupled with decolonization (or suppres-
sion) treatment of MRSA carriers, may have a part to play in
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preventing MRSA infections. As of November 2008, only 18%
and 34% of hospitals were screening all admissions and elective
patients, respectively [78]. Furthermore, a point prevalence
study in 2011 (encompassing 86% of hospitals) found that
only 61% of acute admissions were being screened, despite
this being national policy; and yet these were more than twice
as likely as elective admissions (2.1% vs 0.9%) to be MRSA pos-
itive [56]. Thus, MRSA screening was unlikely to have been a
primary cause of the major reductions in MRSA BSIs in En-
gland seen between 2006 and 2009.
There is evidence that exposure to antibiotics such as cephalo-
sporins or ﬂuoroquinolones can increase the risk of MRSA infec-
tion [72–74]. Progress in improving information and tracking
of hospital antibiotic prescribing has been limited in England,
largely because of delays in developing electronic prescribing.
Nevertheless, marked shifts in antibiotic prescribing did occur
post-2007, probably largely in response to guidance to reduce
the risk of CDI [85, 86]. There were signiﬁcant successive decreas-
es between 2007 and 2010 in the proportions of patients with CDI
in England who had received either cephalosporins or ﬂuoroquin-
olones [85]. Hence, at a time of increased compliance with IPC
measures to reduce MRSA transmission, the selective pressure
for MRSA due to antimicrobial prescribing was also changing.
As mentioned earlier, the multimodal nature of the interventions
precludes us drawing conclusions about the relative importance of
individual components. In reality, this limitation is shared by
most infection prevention campaigns [67].
CONCLUSIONS
In conclusion, we emphasize that multiple major changes in
practice occurred in hospitals in England during the ﬁrst decade
of the present millennium, in response to an extensive IPC pro-
gram. It is now commonplace for hospitals to diagnose no
MRSA BSIs for months at a time. However, the success story
of the control of MRSA BSI (and CDI) is tempered by emergent
HCAI threats, notably caused by Gram-negative bacilli, includ-
ing multiple antibiotic-resistant strains. For example, numbers
of Escherichia coli BSIs in England are increasing [87], and they
are now approximately 4 times more common than was MRSA
BSI at its peak incidence [14]. Thus, there remain considerable
challenges in the prevention of infection that will require target-
ed measures and continued comprehensive surveillance.
Supplementary Material
Supplementarymaterial is available online atOpen Forum Infectious Diseases
(http://OpenForumInfectiousDiseases.oxfordjournals.org/).
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